Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
Source: SeekingAlpha
2026-02-27 06:33:45 ET
The Tide Has Not Turned YET
In my January 25, 2026 article , I argued that the tide may be turning for Novo Nordisk ( NVO ), the underdog relative to its archrival Eli Lilly ( LLY ) after the FDA approval of oral Wegovy. Since then, several events have conspired to punish the stock severely, making a mockery of my call....
Read the full article on Seeking Alpha
For further details see:
Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
Novo Nordisk - Class B
NASDAQ: NONOF
NONOF Trading
-0.75% G/L:
$38.46 Last:
16,693 Volume:
$38.50 Open:
NONOF Latest News
NONOF Stock Data
$217,715,792,624
1,607,906,287
N/A
1546
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
